Skip to main content
. 2024 Feb 12;12(2):e008189. doi: 10.1136/jitc-2023-008189

Figure 6.

Figure 6

OS in patients in the all-treated population after adjustments using (A) IPCW (primary analysis) and (B) TSE, RPSFT, and IPE (sensitivity analyses) methodologies. Chemo, chemotherapy; IPCW, inverse probability of censoring weighting; IPE, iterative parameter estimation; IPI, ipilimumab; NIVO, nivolumab; OS, overall survival; RPSFT, rank-preserving structural failure time; TSE, two-stage estimation; w/o, without.